Sulfatide Inhibits Growth of Fibroblasts and Is a Potential Treatment against Fibrosis

Abstract

Fibrosis of vital organs such as the lungs, liver, and kidneys is a serious condition without effective causal treatment. Here, we suggest the use of the sphingolipid sulfatide and its isoform C16, which we have found to inhibit the growth of fibroblasts. In the lungs, sulfatide can be easily administered via an inhalation spray. Alternatively, fenofibrate, an anti-cholesterol drug with no major side effects, may be used, as it enhances the body’s own production of sulfatide.

Keywords

Sulfatide / Fibroblast / Fibrosis / Lung / Liver / Kidney / MASH / NAFLD

Author Contributions

Conceptualization, K.B.; Writing—Original Draft Preperation, R.T. and K.B.; Writing—Review & Editing, R.T. and K.B.

Ethics Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No novel data was generated in this study.

Funding

This research received no external funding.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Koudstaal T, Funke-Chambour M, Kreuter M, Molyneaux PL, Wijsenbeek MS. Pulmonary fibrosis: From pathogenesis to clinical decision-making. Trends Mol. Med. 2023, 29, 1076-1087. doi:10.1016/J.MOLMED.2023.08.010.

[2] Caputo F, Penitenti F, Bergonzoni B, Lungaro L, Costanzini A, Caio G, et al. Alcohol use disorders and liver fibrosis: An update. Minerva Med. 2024, 115, 354-363. doi:10.23736/S0026-4806.24.09203-6.

[3] Galsgaard KD. The Vicious Circle of Hepatic Glucagon Resistance in Non-Alcoholic Fatty Liver Disease. J. Clin. Med. 2020, 9, 4049. doi:10.3390/JCM9124049.

[4] Bataller R, Brenner DA. Liver fibrosis. J. Clin. Investig. 2005, 115, 209-218. doi:10.1172/JCI24282.

[5] Younossi ZM, Stepanova M, Al Shabeeb R, Eberly KE, Shah D, Nguyen V, et al. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatol. Commun. 2024, 8, e0352. doi:10.1097/HC9.0000000000000352.

[6] Yamashita N, Kramann R. Mechanisms of kidney fibrosis and routes towards therapy. Trends Endocrinol. Metab. 2024, 35, 31-48. doi:10.1016/J.TEM.2023.09.001.

[7] Roeske-Nielsen A, Månsson JE, Tekin H, Rieneck K, Bendtzen K, Buschard K. Sulfatide inhibits fibroblast growth, activation and oxidative stress induced by ectopic insulin. Diabetes Obes. Metab. 2023, 25, 2514-2525. doi:10.1111/DOM.15123.

[8] Delgado A, Casas J, Llebaria A, Abad JL, Fabrias G. Inhibitors of sphingolipid metabolism enzymes. Biochim. Biophys. Acta 2006, 1758, 1957-1977. doi:10.1016/J.BBAMEM.2006.08.017.

[9] Sadhasivam S, Britzi M, Zakin V, Kostyukovsky M, Trostanetsky A, Quinn E, et al. Rapid Detection and Identification of Mycotoxigenic Fungi and Mycotoxins in Stored Wheat Grain. Toxins 2017, 9, 302. doi:10.3390/toxins9100302.

[10] Holm LJ, Haupt-Jorgensen M, Giacobini JD, Hasselby JP, Bilgin M, Buschard K. Fenofibrate increases very-long-chain sphingolipids and improves blood glucose homeostasis in NOD mice. Diabetologia 2019, 62, 2262-2272. doi:10.1007/S00125-019-04973-Z.